Advertisement
Canada markets open in 2 hours 17 minutes

  • S&P/TSX

    22,265.05
    -108.35 (-0.48%)
     

  • S&P 500

    5,306.04
    +1.32 (+0.02%)
     

  • DOW

    38,852.86
    -216.74 (-0.55%)
     

  • CAD/USD

    0.7315
    -0.0022 (-0.30%)
     

  • CRUDE OIL

    80.42
    +0.59 (+0.74%)
     

  • Bitcoin CAD

    92,668.31
    -1,032.30 (-1.10%)
     

  • CMC Crypto 200

    1,464.58
    -20.12 (-1.36%)
     

  • GOLD FUTURES

    2,346.70
    -9.80 (-0.42%)
     

  • RUSSELL 2000

    2,066.85
    -2.82 (-0.14%)
     

  • 10-Yr Bond

    4.5420
    +0.0750 (+1.68%)
     

  • NASDAQ futures

    18,814.50
    -126.00 (-0.67%)
     

  • VOLATILITY

    14.08
    +1.16 (+8.99%)
     

  • FTSE

    8,230.43
    -23.75 (-0.29%)
     

  • NIKKEI 225

    38,556.87
    -298.50 (-0.77%)
     

  • CAD/EUR

    0.6744
    -0.0008 (-0.12%)
     

Reinvent Biologics Adds New Allograft and Synthetic Product Lines, Expands Genius Concentration System Line

ACCESSWIRE

FORT WORTH, TX / ACCESSWIRE / September 29, 2017 / Innovative biologics company, Reinvent Biologics, announced the addition of two new product lines - and expansion of an existing product line - all to make their debut at the North American Spine Society annual conference set for Oct. 25-28 in Orlando, Florida.

The Einstein line of allograft bone includes an Inductive Bone Matrix (IBM), a Demineralized Bone Matrix (DBM), and a Compressive Bone Scaffold (CBS). All Einstein products are 100% human bone and are verified for osteoinductivity post-sterilization prior to release for distribution. Wizard is a line of synthetic bone-graft substitutes comprised of beta-tricalcium phosphate (TCP) granules and a calcium phosphate (CAP) flowable cement.

The Genius Concentration System product line has been expanded to include a larger-capacity option for the processing of blood and bone-marrow aspirate.

"When we launched the company last year, our testing indicated we could deliver more viable components from 30mL of blood and bone-marrow aspirate than many devices did from 60mL," Reinvent Biologics CEO, Bryant Gaines, said. "As interest in using biologics to augment bone healing continues to increase, it makes sense to accommodate physician demand for higher output volume. The addition of a variety of allograft and synthetic scaffolds allows the physician the option of selecting what is best for each situation - and it provides our distributors another tool in their sales bag."

ADVERTISEMENT

Last year, Reinvent Biologics introduced the Genius Concentration System, which utilizes a unique vertical centrifugation design for processing blood and bone marrow aspirate. Through these biologics-based product portfolio extensions, Reinvent Biologics is poised to further penetrate the growing biologics market. A recent market research report predicted the global orthopedic biologics market could reach $5.8 billion by 2018, with a compounded annual growth rate of 5.9%. Due to the highly fragmented landscape, the team at Reinvent believes there is great potential for a company offering "game-changing" products. Reinvent Biologics distributes its products through a network of independent distributors.

Contact:

Joseph Moore
Vice President
Reinvent Biologics
(817) 736-1557

SOURCE: Reinvent Biologics